Discovery Center of AstraZeneca @AstraZeneca

Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.

Picture: Boehmert & Boehmert

The Enlarged Board of Appeal (EBoA) of the European Patent Office will decide upon a question of high relevance for patents in the field biotechnology. The question to be decided concerns the interpretation of what has been “made available to the public”.

The site of the future modern life science campus within easy reach of the city.  Picture: ©?Lukas Görlach

The city is investing in the future by establishing a modern campus and strengthening Mainz as a hub for life sciences. Space with convenient transport connections close to the city centre is available to found or relocate start-ups, companies and research facilities.

In 2021, Metrion Biosciences moved into its labs in Cambridge, UK. © Metrion Biosciences Ltd

Cambridge-based Metrion Biosciences Ltd has secured £3.5m in new equity financing – led by Maven Capital Partners and a £1m contribution from existing investor, Gresham House Ventures.

Acies Bio offers efficient development and scailing of microbial technologies. Picture: © aciesbio

To address the demands of a growing population and enhance food and nutrition security, a transition from traditional chemical-derived production is essential. Biomanufacturing, known for its efficient use of natural resources, offers an ideal solution. Acies Bio recently added fermentation capacity and more versatile equipment for downstream processing and formulation.

Under a high magnification of 10,000X, this digitally-colorized scanning electron microscopic (SEM) image shows a strain of Staphylococcus aureus bacteria taken from a vancomycin intermediate resistant culture (VISA). © CDC/Janice Haney Carr

Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVacc’s preclinical Staphylococcus aureus vaccine LBT-SA7 (formerly IBT-V02) in case of Phase I success.

Picture: © Cohesion Bureau

Continuing geopolitical uncertainty has perpetuated volatility in global markets, exacerbated by higher inflation and interest rates. The impact has left the biotech market in a limbo as investors eschew riskier investments, but there are signs of a potential recovery ahead.

© wikipedia.org - Richard Ying et Tangui Morlier

The French Republicans have tabled a bill in the National Assembly aimed at banning the commercialisation of cell-based meat in France.

Aerial view at EFPL where the technology was established. © EFPL

Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318.

PI_Sino_1860_1046_Mittel.png

Cell-free protein synthesis (CFPS) systems allow rapid protein production in vitro without the need for living cells, offering distinct advantages.